Objective The aim of this study was to compare the efficacy and safety of paclitaxel plus carboplatin at two dose levels in treatment of elderly advanced JNSCLC patients. Methods Total of 62 elderly patientswith advanced JNSCLC diagnosed pathologically were divided into low-dose group ( according to body surface area, paclitaxel 70 mg/m2 and cisplatin 20 mg/m2 iv drip for 3 hours on dl , 8 ) or regular-dose group ( paclitaxel 90 mg/ m2 and cisplatin 25 mg/m2 iv drip for 3 hours on dl , 8 ). The chemotherapy was repeated every 21 days and the efficacy and toxicity were then evaluated. Results The overall response rates of low-dose group and regular dose group were 45. 5% and 47. 5% respectively, and no significant difference was seen between two groups ( x 2= 0. 024, P > 0. 05 ). The main toxicities were hypoplasia of bonemarmw, alopecie and hypodynamia, and other side effects were mild. All of these could be tolerated by patients. Conclusion The combination therapy of low-dose paclitaxel plus cisplatin can be the ideal chemotherapy protocol with tolerable toxicity for patients with advanced JNSCLC.%目的 本研究旨在比较不同剂量紫杉醇联合卡铂治疗老年晚期非小细胞肺癌(NSCLC)患者的毒副反应及疗效.方法 62例老年晚期NSCLC患者被分为结果低剂量和常规剂量两组,根据体表面积,前者给予70 mg/m2和20 mg/m2,第1、8天静滴3小时.后者给予90 mg/m2和25 mg/m2,第1、8天静滴3小时.21天为一周期,随访疗效和毒副作用.结果 低剂量组和常规剂量组的总体有效率分别为45.5%与47.5%,差异没有统计学意义(P>0.05),常见的不良反应有骨髓移植、恶性呕吐、脱发等,其他不良反应,均可耐受.结论 低剂量紫杉联合顺铂治疗老年晚期NSCLC疗效较好,毒副作用可以耐受,值得临床推广应用.
展开▼
